Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

July 16, 2020July 16, 2020

Reolysin-Kyprolis Combo Elicits Promising Clinical Responses in Phase 1B Trial

News

When given in combination with Kyprolis (carfilzomib), the investigative therapy Reolysin (pelareorep) elicits a strong inflammatory response — and promising clinical responses — in people with relapsed or refractory multiple myeloma, a ... Read more

June 26, 2020June 26, 2020

Oncopeptides Reports Positive Results from HORIZON Trial of Melflufen Combo

News

The combination therapy of melflufen (melphalan flufenamide) and dexamethasone continues to be safe and to elicit deep and durable responses in hard-to-treat patients with relapsed or refractory multiple myeloma, ... Read more

June 24, 2020June 24, 2020

Belantamab Mafodotin Continues to Show Promise in Advanced Myeloma Trials

News

Belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, continues to show promise when used alone or in combination with other approved therapies to treat people with relapsed or refractory multiple myeloma, ... Read more

June 22, 2020June 22, 2020

JNJ-4528 Continues to Show Strong, Durable Responses in Trial

News

Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528, continues to lead to strong and durable responses in all patients with relapsed or refractory disease who are participating ... Read more

June 12, 2020June 12, 2020

Xpovio Triple Combo Before FDA for Previously Treated Myeloma Patients

News

Karyopharm Therapeutics is asking that Xpovio (selinexor) be approved with Velcade (bortezomib) and low-dose dexamethasone to treat people with multiple myeloma after at least one line of therapy. The request ... Read more

June 5, 2020June 5, 2020

New Under-the-skin Darzalex Formulation Approved in EU

News

The European Commission (EC) has approved a new under-the-skin (subcutaneous), fixed-dose formulation of Janssen’s Darzalex (daratumumab) for the treatment of adults with multiple myeloma. The approval of the new ... Read more

May 18, 2020May 18, 2020

FDA Asks for More Data on Ide-cel as Potential Multiple Myeloma Therapy

News

The U.S. Food and Drug Administration (FDA) asked for more information from Bristol Myers Squibb and Bluebird Bio as it considers a request to approve their lead CAR T-cell therapy — idecabtagene ... Read more

April 13, 2020April 13, 2020

Bristol Myers, Bluebird Bio Seek FDA Approval of Ide-cel to Treat Advanced Multiple Myeloma

News

Bristol Myers Squibb and Bluebird Bio are seeking U.S. approval of their lead investigational CAR T-cell therapy — idecabtagene vicleucel (ide-cel; bb2121) — for the treatment of heavily pre-treated ... Read more

March 4, 2020March 23, 2020

FDA Approves Sarclisa Combo to Treat Advanced Multiple Myeloma

News

The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc), in combination with Pomalyst (pomalidomide) and dexamethasone, to treat adults with relapsed or refractory multiple myeloma who tried at least two ... Read more

February 19, 2020February 19, 2020

Darzalex Combo Leads to Durable Responses in Patients With Advanced Multiple Myeloma, Follow-up Data Show

News

Janssen‘s Darzalex (daratumumab) in combination with Revlimid (lenalidomide) and dexamethasone continues to lead to strong and durable responses, and prolong the time until disease worsening in patients with relapsed ... Read more

Pin It on Pinterest